Click here to view online. Add this email to your safelist.
Enhertu granted Breakthrough Therapy Designation in the US for patients with HER2-low metastatic breast cancer
27 April 2022
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been granted Breakthrough Therapy Designation (BTD) in the US for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-negative) breast cancer who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy. Patients with hormone receptor (HR) positive breast cancer should additionally have received or be ineligible for endocrine therapy.
|
|||||
|
|||||
|
For more information please visit astrazeneca.com. If you would like to unsubscribe please click here. |
